CGC241220P12000
- 8.31
- 0.000.00%
Canopy Growth Newsroom
ATB Capital Markets Downgrades Canopy Growth(CGC.US) to Sell Rating, Cuts Target Price to $2.79
Canopy Growth (CGC) Was Downgraded to a Sell Rating at ATB Capital Markets
Canopy Growth Corp Price Target Cut to C$4.00/Share From C$6.00 by ATB Capital
Canopy Growth Corp. Price Target Cut to C$3.50/Share From C$5.00 by Canaccord Genuity
Analysts Offer Insights on Healthcare Companies: Novavax (NVAX), Regulus (RGLS) and Canopy Growth (CGC)
Piper Sandler Reaffirms Their Sell Rating on Canopy Growth (CGC)
Piper Sandler Adjusts Price Target on Canopy Growth to $2 From $3, Maintains Underweight Rating
Canopy Gwth Analyst Ratings
Piper Sandler Maintains Underweight on Canopy Gwth, Lowers Price Target to $2
Piper Sandler Maintains Canopy Growth at Underweight, Cuts Price Target to US$2.00 on Weak Sales
Analysts Conflicted on These Healthcare Names: Cooper Co (COO), Canopy Growth (CGC) and BioMarin Pharmaceutical (BMRN)
Analysts Conflicted on These Healthcare Names: Canopy Growth (CGC), Ultragenyx Pharmaceutical (RARE) and Roivant Sciences (ROIV)
Canopy Growth Sell Rating Justified by Stagnant Sales, High Valuation, and Profitability Concerns
Canopy Growth's (TSE:WEED) US Invasion Falls Flat With Shareholders
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bruker (BRKR), Canopy Growth (CGC) and Medtronic (MDT)
Piper Sandler Sticks to Its Sell Rating for Canopy Growth (CGC)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Canopy Growth (CGC) and Vertex Pharmaceuticals (VRTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Canopy Growth (CGC)
Canopy Growth's Stock Faces Sell Rating Amid Lower Sales, Regulatory Challenges, and Legal Risks